Exelixis Inc
$ 44.01
0.87%
23 Feb - close price
- Market Cap 11,799,615,000 USD
- Current Price $ 44.01
- High / Low $ 44.49 / 43.45
- Stock P/E 15.83
- Book Value 8.23
- EPS 2.78
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.19 %
- ROE 0.36 %
- 52 Week High 49.62
- 52 Week Low 32.38
About
Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.
Analyst Target Price
$47.17
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-10 | 2025-10-27 | 2025-07-28 | 2025-04-28 | 2025-02-04 | 2024-10-29 | 2024-08-06 | 2024-04-30 | 2024-02-06 | 2023-11-01 | 2023-08-01 | 2023-05-09 |
| Reported EPS | 0.97 | 0.78 | 0.75 | 0.62 | 0.55 | 0.4 | 0.77 | 0.2 | 0.27 | 0.1 | 0.25 | 0.12 |
| Estimated EPS | 0.8 | 0.6931 | 0.64 | 0.3666 | 0.4918 | 0.35 | 0.3 | 0.24 | 0.21 | 0.1 | 0.16 | 0.15 |
| Surprise | 0.17 | 0.0869 | 0.11 | 0.2534 | 0.0582 | 0.05 | 0.47 | -0.04 | 0.06 | 0 | 0.09 | -0.03 |
| Surprise Percentage | 21.25% | 12.5379% | 17.1875% | 69.1217% | 11.8341% | 14.2857% | 156.6667% | -16.6667% | 28.5714% | 0% | 56.25% | -20% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.7696 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EXEL
2026-02-23 19:15:08
Exelixis, Inc. (EXEL) is highlighted as a strong biotechnology company focused on novel cancer therapies, with a market cap of $11.7 billion and current stock price of $43.63. The company shows stable market performance, attractive valuation, robust revenue growth, and strong financial health, including a high return on equity and substantial free cash flow. Despite mixed analyst ratings, an average price target of $47.17 suggests an 8.11% potential upside, making it a compelling prospect for growth-oriented investors due to its strategic partnerships and promising pipeline.
2026-02-21 02:02:43
Exelixis, a biotech company, has shown strong financial performance over the past five years, largely due to its successful cancer drug, Cabometyx. While Cabometyx faces potential generic competition by early 2030, Exelixis is developing a new cancer medicine, zanzalintinib, and has other pipeline candidates to mitigate this risk. The company's strategic development and strong market position make it a compelling investment consideration.
2026-02-21 01:36:32
Exelixis director Jack L. Wyszomierski sold 99,574 shares of common stock for approximately $4.38 million on February 18, 2026, under a Rule 10b5-1 trading plan. On the same day, Wyszomierski also exercised options to acquire 20,634 shares. The company recently reported a Q4 2025 EPS beat, although revenue missed expectations, leading H.C. Wainwright to raise its price target to $54 and Citizens to reaffirm its Market Outperform rating with a $50 price target.
2026-02-20 00:57:56
Exelixis director Julie Smith sold approximately $4.68 million worth of company stock on February 17 and 18, 2026, after exercising options to acquire the shares. These transactions involved 106,539 shares overall, with sales prices ranging from $43.33 to $44.50 and option exercise prices between $18.19 and $21.69. Following the sales, Smith directly owns 20,590 Exelixis shares.
2026-02-20 00:19:52
Julie Smith, a director at Exelixis, Inc., recently sold approximately $4.68 million worth of common stock after exercising options. The transactions involved 106,539 shares sold across February 17 and 18, 2026, at prices between $43.33 and $44.50. This comes as Exelixis shows strong stock momentum, gaining 26% over the past year, while recent company news includes exceeding EPS forecasts for Q4 2025 and positive analyst ratings for its cancer treatment zanzalintinib.
2026-02-19 16:19:52
Exelixis director Oliver Bob sold 30,250 shares of common stock for approximately $1.3 million on February 13, 2026, and also exercised options to acquire 9,088 shares. Despite these sales, the company maintains an excellent financial health score and recently surpassed its fourth-quarter 2025 EPS estimates. Analysts have reiterated positive ratings and price targets, bolstered by insights into their cancer drug zanzalintinib.
